tbuckley/cabot-search huggingface dataset:
Sequential treatment of locally advanced squamous cell carcinoma of the oropharynx (LASCCO) using docetaxel, cisplatin, and 5-fluorouracil (TPF) induction regimen: Retrospective results from a single institution.
Authors: Z. D. Lucas, J. Appiah, J. Mercado, R. Dowsett, J. Spiro, U. P. Hegde
Journal: Journal of Clinical Oncology (2011)

e16015 Background: Oropharyngeal squamous cell carcinoma (OSCC) accounts for over 30% of the head and neck cancer. Encouraging results have been published with TPF regimen as induction therapy (IT) in a sequential treatment design of treating LASCCO followed by chemoradiation therapy (CRT). We are reporting our experience of using TPF regimen for IT of LASCCO followed by CRT therapy at the University of Connecticut Health Center. Methods: Electronic charts of patients treated at the Neag Cancer Center of the University of Connecticut Health Center for LASCCO stage III/IV, who received IT with two cycles of standard TPF regimen followed by CRT between January 2004 and June 2010, were reviewed. Patients with concurrent malignancy were excluded. Demographics, risk factors, treatment regimen and toxicities and survival data were collated. Results: There were twenty-five patients included in the study with 20 males and 5 females. Median age at diagnosis was 56 years (range 38-85). Cisplatin was substituted with carboplatin on day 1 at a dose of AUC 5, in those who had renal insufficiency. Evaluation of response was done after 2 weeks of IT. The overall response rate was 100% after two cycles of TPF regimen with 20% being complete responses (CR). Following IT, mucositis (34.8%) and febrile neutropenia (21.7%) were expected side effects. Concurrent CRT consisted of weekly carboplatin at a dose of 1.5 AUC/week and paclitaxel at 45mg/m2/week along with radiation therapy 5 days a week for 7 weeks, using an intensive modulation radiation therapy (IMRT) source. Median radiation dose was 7000 cGY. Chemotherapy had to be interrupted in 30% of patients because of neutropenia during CRT. With a median follow up period of 18 months, 4 (16%) patients died– 2 of recurrent disease, 1 from sudden death on day 3 of IT, probably related to 5-FU-associated cardiovascular event, and 1 developed pulmonary embolism. Twenty-one out of 25 patients are in CR and doing well. Median progression-free survival is 18 months and median overall survival is 21 months. Conclusions: TPF regimen is effective and well tolerated IT regimen in patients with LAOSCC.
Erratum for the Research Article: “Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa” by V. Sebastiano, H. H. Zhen, B. Haddad, E. Bashkirova, S. P. Melo, P. Wang, T. L. Leung, Z. Siprashvili, A. Tichy, J. Li, M. Ameen, J. Hawkins, S. Lee, L. Li, A. Schwertschkow, G. Bauer, L. Lisowski, M. A. Kay, S. K. Kim, A. T. Lane, M. Wernig, A. E. Oro
Journal: Science Translational Medicine (2014)
Airway Exosomes from Asthmatics Modulate Differential T Helper Responses
Authors: Jessy Deshane, Kenneth Hough, Landon Wilson, Marion Spell, Jennifer L. Trevor, Diptiman Chanda, Jose Rodriguez Dager, Yong Wang, Stephen Barnes, Veena Antony, Chad Steele, Mark Dransfield, Steven Duncan, Jeevan Prasain, Victor Thannickal
Journal: Journal of Allergy and Clinical Immunology (2017)
Successful Treatment of Primary Refractory Bulky Diffuse Large B-Cell Lymphomas with Concomitant Radio-Chemotherapy Followed by Autologous Stem Cell Transplantation : A Single Center Experience
Authors: Marie-Anne Couturier, Elise Champeaux-Orange, Delphine Senecal, S.éverine Lissandre, Lotfi Benboubker, Isabelle Barillot, Gilles Calais, Philippe Colombat, Emmanuel Gyan
Journal: Blood (2008)
Effectiveness of seasonal influenza vaccination in community-dwelling elderly people: an individual participant data meta-analysis of test-negative design case-control studies
Authors: Maryam Darvishian, Edwin R van den Heuvel, Ange Bissielo, Jesus Castilla, Cheryl Cohen, Helene Englund, Giedre Gefenaite, Wan-Ting Huang, Sacha la Bastide-van Gemert, Iván Martinez-Baz, Johanna M McAnerney, Genevie M Ntshoe, Motoi Suzuki, Nikki Turner, Eelko Hak
Journal: The Lancet Respiratory Medicine (2017)
IgM anti-dsDNA autoantibodies are the main antinuclear reactivity induced by infliximab but not etanercept treatment in vivo: Biological and clinical implications
Authors: Leen De Rycke, Dominique Baeten, Elli Kruithof, Filip Van Den Bosch, Eric Veys, Filip De Keyser
Journal: Annals of the Rheumatic Diseases (2005)
Reply: Naturally Occurring Human Antibody to Neuraminidase-Treated Human Lymphocytes
Authors: G. Nicholas Rogentine
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Reply: Naturally Occurring Human Antibody to Neuraminidase-Treated Human Lymphocytes G. Nicholas Rogentine, Jr., M.D. G. Nicholas Rogentine, Jr., M.D. Immunology Branch Division of Cancer Biology and Diagnosis National Cancer Institute, Bethesda, Maryland 20014. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 56, Issue 2, February 1976, Pages 211–212, https://doi.org/10.1093/jnci/56.2.211-a Published: 01 February 1976
Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma
Authors: Madeleine Duvic, Youn H. Kim, Pier Luigi Zinzani, Steven M. Horwitz
Journal: Clinical Cancer Research (2017)

Purpose: Pralatrexate is a folic acid analogue metabolic inhibitor similar to methotrexate, which has shown tolerability and efficacy with an overall response rate of 45% in a phase I dose deescalation study of patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL).Experimental Design: The object of this phase I/II open-label, multicenter clinical trial was to determine the MTD and recommended dose of pralatrexate plus oral bexarotene in 34 patients with relapsed/refractory CTCL who had failed prior systemic therapies. Pralatrexate was administered by intravenous push at 15 mg/m2 given weekly 3 weeks out of 4 weeks with daily oral bexarotene (150 or 300 mg/m2), levothyroxine, atorvastatin, folate, and with B12 every 2 months.Results: At the MTD of 15 mg/m2 bexarotene and 15 mg/m2 pralatrexate, the response rate was 60% [4 complete responses (CR), 14 partial responses (PR)], the maximum observed response duration was 28.9+ months, and duration of response for 4 CRs ranged from 9.0 to 28.3 months. The median progression-free survival was 12.8 months (0.5-29.9). Mucositis was the most common adverse event.Conclusions: The combination of pralatrexate (15 mg/m2) and oral bexarotene (150 mg/m2) is active with high response rates and minimal toxicity for cutaneous T-cell lymphomas. Clin Cancer Res; 23(14); 3552-6. ©2017 AACR.
Safety of Bronchial Thermoplasty in High Risk Patients with Severe Asthma
Authors: Rana Kanaan, Charlie Strange, Douglas Kyle Hogarth, Walter Mark Boomer, Lisa M. Kopas, Shanaya Suchak, Michelle Cornacchia, Julia Behrend, Nicholas J. Pastis, John B. Cox
Journal: Journal of Allergy and Clinical Immunology (2017)
Rapid transcriptional plasticity of duplicated gene clusters enables a clonally reproducing aphid to colonise diverse plant species
Authors: Thomas C. Mathers, Yazhou Chen, Gemy Kaithakottil, Fabrice Legeai, Sam T. Mugford, Patrice Baa-Puyoulet, Anthony Bretaudeau, Bernardo Clavijo, Stefano Colella, Olivier Collin, Tamas Dalmay, Thomas Derrien, Honglin Feng, Toni Gabaldón, Anna Jordan, Irene Julca, Graeme J. Kettles, Krissana Kowitwanich, Dominique Lavenier, Paolo Lenzi, Sara Lopez-Gomollon, Damian Loska, Daniel Mapleson, Florian Maumus, Simon Moxon, Daniel R. G. Price, Akiko Sugio, Manuella van Munster, Marilyne Uzest, Darren Waite, Georg Jander, Denis Tagu, Alex C. C. Wilson, Cock van Oosterhout, David Swarbreck, Saskia A. Hogenhout
Journal: Genome biology (2017)

The prevailing paradigm of host-parasite evolution is that arms races lead to increasing specialisation via genetic adaptation. Insect herbivores are no exception and the majority have evolved to colonise a small number of closely related host species. Remarkably, the green peach aphid, Myzus persicae, colonises plant species across 40 families and single M. persicae clonal lineages can colonise distantly related plants. This remarkable ability makes M. persicae a highly destructive pest of many important crop species.To investigate the exceptional phenotypic plasticity of M. persicae, we sequenced the M. persicae genome and assessed how one clonal lineage responds to host plant species of different families. We show that genetically identical individuals are able to colonise distantly related host species through the differential regulation of genes belonging to aphid-expanded gene families. Multigene clusters collectively upregulate in single aphids within two days upon host switch. Furthermore, we demonstrate the functional significance of this rapid transcriptional change using RNA interference (RNAi)-mediated knock-down of genes belonging to the cathepsin B gene family. Knock-down of cathepsin B genes reduced aphid fitness, but only on the host that induced upregulation of these genes.Previous research has focused on the role of genetic adaptation of parasites to their hosts. Here we show that the generalist aphid pest M. persicae is able to colonise diverse host plant species in the absence of genetic specialisation. This is achieved through rapid transcriptional plasticity of genes that have duplicated during aphid evolution.
Evaluation of PD-1 and PD-L1 expression on CTCs isolated from non-small cell lung cancer (NSCLC) tumor patients
Authors: G. Kallergi, D. Aggouraki, P. Katsarlinos, E.K. Vetsika, E. Lagoudaki, F. Koinis, A. Koutsopoulos, V. Georgoulias, A. Kotsakis
Journal: Annals of Oncology (2016)
ER-Stress-Induced Suppression of HLA-E on Bortezomib-Evading Malignant Plasma Cells Dramatically Enhances Their Susceptibility to NK Cell Killing: Identification of an Achilles Heel in Myeloma Cells That Can be Utilized to Prevent Disease Relapse Following Bortezomib Treatment
Authors: Mattias Carlsten, Ali Namazi, Robert N. Reger, Maria Berg, Richard W. Childs
Journal: Blood (2015)
CBIO-19. DISSECTING THE MULTICELLULAR ECOSYSTEM OF HUMAN GLIOBLASTOMA TUMORS USING SINGLE CELL MASS CYTOMETRY
Authors: Nalin Leelatian, Justine Sinnaeve, Bret Mobley, Kyle Weaver, Reid Thompson, Lola Chambless, Rebecca Ihrie, Jonathan Irish
Journal: Neuro-Oncology (2016)

The diversity and plasticity of cells in glioblastoma may be the primary cause of its deadly prognosis. Characterizing the identity, signaling, and functional biology of individual cells within glioblastoma will power the development of new therapies that overcome resistance and recurrence by targeting multiple cancer cell subtypes while sparing non-malignant cells. High-throughput single cell analysis with mass cytometry (CyTOF) is well-suited for this purpose, since it can simultaneously measure 40 or more proteins and phospho-proteins per cell. This study’s goal was to 1) develop robust protocols for preparing intraoperative glioblastoma tissue as viable single cell suspensions for ex vivo analysis and cryopreservation and 2) to use CyTOF to characterize preservation of key cell subsets in the tumor microenvironment. A 34-antibody panel comprehensively characterized the cellular ecosystem of glioblastoma using ~50,000 cells per tumor. Tracked cell types included subsets of cancer cells (e.g. expressing variable SOX2, PDGFRα, c-MET, or GFAP), infiltrating T cells (CD45+CD3+), microglia (CD45+CD64+), ependymal cells (CD45-CD24+), vascular cells (CD45-CD31+), pericytes (CD45-αSMA+), neural-like cells (CD45-CD31-TUJ1+) and astrocyte-like cells (CD45-CD31-S100B+). These cell types were tracked for viability and abundance in experiments testing key variables in tumor preparation, including disaggregation enzymes and times. Following this optimization, computational analysis using viSNE (Amir et al., Nature Biotechnology 2013) and complementary tools (Diggins et al., Methods 2015) revealed tumor cells with novel phenotypes. Comparison across multiple glioblastoma tumors determined which subsets were specific to individual tumors and which were observed repeatedly. In conclusion, this work developed robust protocols for single cell analysis of intraoperative glioblastoma tissue and revealed unexpected new glioblastoma tumor cell types that can now be tested ex vivo for compound response, propagated as spheres or patient derived xenografts, and isolated for genomic analysis.
Prognostic significance of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma: the ARQ197-215 study
Authors: N. Personeni, L. Giordano, G. Abbadessa, C. Porta, I. Borbath, B. Daniele, S. Salvagni, J.L. Van Laethem, H. Van Vlierberghe, J. Trojan, E.N. De Toni, A. Weiss, S. Miles, A. Gasbarrini, M. Lencioni, M.E. Lamar, D. Shuster, B. Schwartz, A. Santoro, L. Rimassa
Journal: Annals of Oncology (2016)
DNA repair metagene signature as a prognostic and predictive factor in molecular breast cancer subtypes.
Authors: Libero Santarpia, Takayuki Iwamoto, Angelo Di Leo, Naoki Hayashi, Martha Stampfer, Cristina Guarducci, William Fraser Symmans, Gabriel N. Hortobagyi, Lajos Pusztai, Bianchini Giampaolo
Journal: Journal of Clinical Oncology (2012)

1012 Background: We aimed to assess the prognostic and predictive role of DNA repair genes in breast cancer (bc) molecular subtypes. Methods: We evaluated Affymetrix gene expression profiling from untreated N- patients (N = 684), neoadjuvant treated tumors with taxanes- (N = 320), anthracyclines- (N = 211), and cisplatin- (N = 22) containing regimens. We assessed within 3 BC molecular subgroups (ER+/HER2-, HER2+, and ER-/HER2-) bimodality distribution, prognosis by association with distant relapse (N = 454, N = 105, and N = 125) and predictive value for likelihood of pathological complete response (pCR) (N = 208, N = 105, and N = 240). Moreover, we explored the function of relevant genes in BC cell lines. Results: Three genes (ERCC2, XRCC3, and RECQL4) showed bimodality in each bc subtype. Eight genes were associated with poor prognosis (including RECQL4) and 1 gene with good prognosis (ATM) [P &lt; .0001] only in ER+/HER2- tumors. Our results suggest a subtype and treatment specific association with pCR although they did not satisfy stringent criteria for false discovery correction. In ER-/HER2- mismatch repair (MR) (MSH2 and MSH6) and MTMR15 genes were associated with response and resistance to taxane-containing regimens, respectively. TOP2A was the only gene associated with response to anthracycline but not taxanes in HER2+ tumors. RECQL4 had a positive trend with higher pCR in both ER+ and ER-/HER2- tumors. In in vitro studies we found that RECQL4 interacts with PARP1 and that the expression of these genes was correlated with sensitivity to chemotherapy and PARP inhibitors. Conclusions: We identified MR genes as potential predictive markers of response to taxanes-based regimens in ER-/HER2-. A novel gene RECQL4 showed bimodal distribution, prognostic value, and a trend for predictive association with response to taxanes-based chemotherapy, which was also confirmed by in vitro analysis. ATM deserves further evaluation as prognostic marker in ER+/HER2-.
Long Term Observation of CML Patients after Imatinib Resistance Associated with BCR-ABL Mutations.
Authors: Andreas Hochhaus, T. Ernst, P. Erben, M. C. Mueller, M. Emig, S. Kreil, P. La Rosée, T. Lahaye, M. Schatz, O. G. Ottmann, S. Schnittger, U. Berger, R. Hehlmann
Journal: Blood (2005)
<i>MED12</i>is recurrently mutated in Middle Eastern colorectal cancer
Authors: Abdul K Siraj, Tariq Masoodi, Rong Bu, Poyil Pratheeshkumar, Nasser Al-Sanea, Luai H Ashari, Alaa Abduljabbar, Samar Alhomoud, Fouad Al-Dayel, Fowzan S Alkuraya, Khawla S Al-Kuraya
Journal: Gut (2017)

Colorectal cancer (CRC) is a common cancer and a leading cause of cancer deaths. Previous studies have identified a number of key steps in the evolution of CRC but our knowledge of driver mutations in CRC remains incomplete. Recognising the potential of studying different human populations to reveal novel insights in disease pathogenesis, we conducted genomic analysis of CRC in Saudi patients.In the discovery phase of the study, we conducted whole genome sequencing of tumour and corresponding germline DNA in 27 patients with CRC. In addition to known driver mutations, we identified three MED12 somatic mutations. In the replication phase, we employed a next-generation sequencing approach to capture and sequence MED12 and other candidate genes in a larger sample of 400 patients with CRC and confirmed the enrichment for recurrent MED12 mutations.In order to gain insight into a plausible biological mechanism for the potential role of MED12 mutations in CRC, we studied CRC cell lines that differ substantially in the expression level of MED12, and found the latter to be correlated inversely with transforming growth factor (TGF)-β signalling and directly with apoptosis in response to chemotherapeutic agents. Importantly, these correlations were replicated when MED12 expression was experimentally manipulated.Our data expand the recently described role of MED12 as a tumour suppressor in other cancers to include CRC, and suggest TGF-β signalling as a potential mediator of this effect.
Improved Nutrition in Adolescents and Young Adults after childhood cancer: INAYA—A pilot study.
Authors: Julia Quidde, Barbara Koch, Carsten Bokemeyer, Gabriele Escherich, Daniel Buchholz, Luzia Valentini, Alexander Stein, Julia von Grundherr
Journal: Journal of Clinical Oncology (2016)

173 Background: By the use of multimodal therapies the chance of cure and survival improves and thus the risk for long-term side effects are increasing in „Adolescents and Young Adult“ cancer survivors (AYAs) . Compared to the general population AYAs have a 5 to 15-fold increased risk of cardiovascular diseases. Therefore, the improvement of modifiable lifestyle risk factors is of importance. Besides general information supplied during survivorship care nutrition habits in AYAs remain bad. Methods: The INAYA trial enrolled AYAs between 18-39 years to receive an intensified individual nutrition counseling based on a 3-day dietary records at 4 defined timepoints. At week 0 and 12 AYAs got personal counseling during follow-up care and consultation hours and at week 2 and 6 by telephone. Primary endpoint was change in nutritional intake measured by the Healthy Eating Index of the European Prospective Investigation into Cancer and Nutrition (HEI-EPIC). Secondary endpoints were (selection): quality of life (QoL), change in weight and waist-hip ratio. Results: 23 AYAs (11 female, 12 male, 21.9 ± 4.3 years of age, BMI: 21.6 ± 1.7 kg/m²) after treatment for childhood malignancies (12x hodgkin lymphoma, 6x leukaemia, 2x sarcoma, 2x carcinoma, 1x blastoma) were included. At baseline 14 patients (pts) were of normal weight, 4 pts overweight and 5 pts underweight (WHO criteria). 56.5% (n = 13) reported gastrointestinal symptoms (e.g. flatulence, change in stool consistency, stomach pain). According to HEI-EPIC a good, moderate and bad nutritional intake was seen in 4.3%, 73.9% and 21.7% of the pts. A high salt intake was seen in 6 pts (26%). Dietary habits improved after nutrition counseling at week 0, 2 and 6. 43.7% (n = 10) took more time to eat, 47.8% (n = 11) increased their fluid intake to ≥ 1.5 l/d and 21.7% (n = 5) changed their weight positively. Up to now 8 pts completed the study. Median HEI-EPIC score improved from 46 points (baseline) to 66 points (week 12). Final results are expected for November 2015. Conclusions: Intensified nutrition counselling improves dietary intake and nutrition status in AYAs.
The MITO8 phase 3 international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum based chemotherapy. A collaboration of MITO, Mango, AGO Study Group, BGOG, ENGOT, and GCIG
Authors: M.C. Piccirillo, G. Scambia, A. Bologna, I. Vergote, K. Baumann, F. Raspagliesi, V. Murgia, C. Pisano, V. Salutari, R. Sorio, G. Ferrandina, C. Sacco, G. Cormio, E. Breda, S. Cinieri, S.C. Cecere, G. Daniele, C. Gallo, F. Perrone, S. Pignata
Journal: Annals of Oncology (2016)
Following Beta-Globin Gene Transfer, the Production of Hemoglobin Depends Upon the Beta-Thalassemia Genotype.
Authors: Laura Breda, Carla Casu, Laura Casula, Dorothy A. Kleinert, Nicoletta Bianchi, Evgenia Prus, Luca Cartegni, Eitan Fibach, Lawrence B. Gardner, Patricia J Giardina, Roberto Gambari, Stefano Rivella
Journal: Blood (2009)
Three-dimensional growth of human endothelial cells in an automated cell culture experiment container during the SpaceX CRS-8 ISS space mission – The SPHEROIDS project
Authors: Jessica Pietsch, Samuel Gass, Stefano Nebuloni, David Echegoyen, Stefan Riwaldt, Christin Baake, Johann Bauer, Thomas J. Corydon, Marcel Egli, Manfred Infanger, Daniela Grimm
Journal: Biomaterials (2017)
Identification of a New Genetic Determinant Controlling Human Hematopoietic Stem Cell Engraftment.
Authors: Katsuto Takenaka, Tatiana K. Prasolava, Jean C.Y. Wang, Steven M. Mortin-Toth, Sam Khalouei, Olga I. Gan, John E. Dick, Jayne S. Danska
Journal: Blood (2007)
Efficacy of sequential treatment with first, second and third generation EGFR inhibitors and role of Hedgehog pathway in the acquisition of resistance in in vivo NSCLC models
Authors: C.M. Della Corte, F. Papaccio, G. Viscardi, G. Esposito, M. Fasano, M.D. Castellone, A. Parascandolo, F. De Vita, M. Orditura, F. Ciardiello, F. Morgillo
Journal: Annals of Oncology (2016)
A 15-Month-Old Boy With Blue-Gray Macules
Authors: Karyn Haitz, Andrew C. Walls, Jennifer T. Huang
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
RNA Electroporation as a New Gene Transfer Method in Hematopoietic Progenitor Cells, Mesenchymal Cells and Activated T-Cells.
Authors: Zwi N. Berneman, Evelien Smits, Peter Ponsaerts, Marc Lenjou, Griet Nijs, Dirk R. Van Bockstaele, Viggo F. Van Tendeloo
Journal: Blood (2004)
Title: A Short Course of Supplementation with Vitamin E Isoform, Gamma Tocopherol (yT), Mitigates Endotoxin-Induced Inflammation in Humans Ex Vivo
Authors: Allison Burbank, Charity G. Duran, Katherine Mills, Martha Almond, Qing Jiang, Michelle L. Hernandez, David B. Peden
Journal: Journal of Allergy and Clinical Immunology (2017)